The effects of Compton camera data acquisition and readout timing on PG imaging for proton range verification.
Compton camera
prompt gamma imaging
proton range verification
proton therapy
Journal
IEEE transactions on radiation and plasma medical sciences
ISSN: 2469-7311
Titre abrégé: IEEE Trans Radiat Plasma Med Sci
Pays: United States
ID NLM: 101705223
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
ppublish
Résumé
The purpose of this study was to determine how the characteristics of the data acquisition (DAQ) electronics of a Compton camera (CC) affect the quality of the recorded prompt gamma (PG) interaction data and the reconstructed images, during clinical proton beam delivery. We used the Monte-Carlo-plus-Detector-Effect (MCDE) model to simulate the delivery of a 150 MeV clinical proton pencil beam to a tissue-equivalent plastic phantom. With the MCDE model we analyzed how the recorded PG interaction data changed as two characteristics of the DAQ electronics of a CC were changed: (1) the number of data readout channels; and (2) the active charge collection, readout, and reset time. As the proton beam dose rate increased, the number of recorded PG single-, double-, and triple-scatter events decreased by a factor of 60× for the current DAQ configuration of the CC. However, as the DAQ readout channels were increased and the readout/reset timing decreased, the number of recorded events decreased by <5× at the highest clinical dose rate. The increased number of readout channels and reduced readout/reset timing also resulted in higher quality recorded data. That is, a higher percentage of the recorded double- and triple-scatters were "true" events (caused by a single incident gamma) and not "false" events (caused by multiple incident gammas). The increase in the number and the quality of recorded data allowed higher quality PG images to be reconstructed even at the highest clinical dose rates.
Identifiants
pubmed: 36092269
doi: 10.1109/trpms.2021.3057341
pmc: PMC9457195
mid: NIHMS1785486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
366-373Subventions
Organisme : NCI NIH HHS
ID : R01 CA187416
Pays : United States
Références
Phys Med Biol. 2015 Oct 7;60(19):7617-35
pubmed: 26389549
Phys Med Biol. 2015 Sep 21;60(18):7085-99
pubmed: 26317610
Med Phys. 2015 Dec;42(12):7090-7
pubmed: 26632062
Radiother Oncol. 2016 Feb;118(2):232-7
pubmed: 26774764
Theranostics. 2013 Sep 19;3(10):731-40
pubmed: 24312147
Z Med Phys. 2019 Feb;29(1):59-65
pubmed: 29858131
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):268-75
pubmed: 20472369
Phys Med Biol. 2014 Dec 21;59(24):7653-74
pubmed: 25415207
IEEE Trans Radiat Plasma Med Sci. 2021 May;5(3):383-391
pubmed: 34056151
Phys Med Biol. 2012 Sep 7;57(17):5459-72
pubmed: 22864267
Sci Rep. 2018 Mar 6;8(1):4100
pubmed: 29511282
Phys Med Biol. 2020 Jun 18;65(12):125004
pubmed: 32320971
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):210-218
pubmed: 28816148
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):920-34
pubmed: 17544003
Phys Med Biol. 2012 Jun 7;57(11):R99-117
pubmed: 22571913
IEEE Trans Radiat Plasma Med Sci. 2020 Mar;4(2):170-183
pubmed: 32258856
Phys Med Biol. 2018 Jan 30;63(3):035019
pubmed: 29380750
Med Phys. 2017 Dec;44(12):6261-6269
pubmed: 29031024
Med Phys. 2018 Nov;45(11):e1036-e1050
pubmed: 30421803
Med Phys. 2012 Apr;39(4):2100-7
pubmed: 22482631
Phys Med Biol. 2014 Oct 7;59(19):5849-71
pubmed: 25207724
Adv Drug Deliv Rev. 2017 Jan 15;109:26-44
pubmed: 27919760
Nat Rev Clin Oncol. 2013 Jul;10(7):411-24
pubmed: 23689752
Phys Med Biol. 2014 Dec 7;59(23):7089-106
pubmed: 25365362
Phys Med Biol. 2011 Feb 21;56(4):1123-37
pubmed: 21263176
Phys Med Biol. 2016 Jul 21;61(14):5149-65
pubmed: 27352107
Phys Med Biol. 2013 Aug 7;58(15):R131-60
pubmed: 23863203
Front Oncol. 2016 Jan 28;6:10
pubmed: 26858937
Phys Med Biol. 2015 Mar 7;60(5):1845-63
pubmed: 25658644
Phys Med Biol. 2014 Sep 21;59(18):5399-422
pubmed: 25157685